Metastatic malignant melanoma; Hodgkin's disease as a second-line therapy [in combination therapy]
Malignant Melanoma: 2-4.5 mg/kg/day x 10/7, which can be repeated at 4 wk intervals. Alternatively 250 mg/ m2 /day IV x 5/7, which can be repeated every 3 wks. Hodgkin's Disease: 150mg/m2 5/7 in combination with other effective drugs. This can be repeated every 4 weeks. Alternatively 375mg/kg m2 on day 1, in combination with other effective drugs, to be repeated every 15 days.Consult specialist literature for further information.
Mode of action
Brands containing this Ingredient
Drug Index 2.0 is hereOur new update features a more powerful search feature and easier login.
issues? Contact us
today. Contact Us
Mode of Action
A synthetic analog of the natu-rally occurring purine precursor 5-amino-1H-imidazole-4-carboxamide, which is thought to exert its cytotoxic effect by inhibiting DNA-synthesis by acting as a purine analog as an alkylating agent and by interacting with SH groups.
It has minimal immunosuppressive activity.
Only physicians experienced in cancer chemotherapy should use it; increased incidence of infections; increased incidence of hemorrhagic complications; blood counts should be performed at least once a week; history of hypersensitivity to it; extravasation of the drug subcutaneously during IV administration may result in tissue damage and severe pain;
Hypersensitivity to the drug
Haemopoietic depression [the most serious common S/E]; hepatic necrosis; anorexia; nausea; vomiting; influenzae-like syndrome; myalgia; alopecia; facial flushing; facial paresthesia; erythematous and urticarial rashes; photo-sensitivity reactions.
Drug interactions: It inhibits xanthine oxidase causing additive hypoglycemic effects when used concurrently with allopurinol; hepatic enzyme inducers may enhance its metabolism.